Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from 89bio

This United Parcel Service Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

On Thursday, Roche Holdings AG (OTC:RHHBY) agreed to acquire 89bio, Inc. (NASDAQ:ETNB) for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for liver and cardiometabolic diseases.

Top 2 Health Care Stocks That May Keep You Up At Night This Month

Top 2 Health Care Stocks That May Keep You Up At Night This Month

As of Sept. 18, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Darden Restaurants, Factset Research And 3 Stocks To Watch Heading Into Thursday

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

5 Analysts Have This to Say About 89bio

Over the past 3 months, 5 analysts have published their opinion on 89bio (NASDAQ:ETNB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

inkl

Read news from The Economist, FT, and more,
with one subscription

89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia

89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia

89bio Inc (NASDAQ: ETNB)

89bio Pulls Back With Market — But Could The Stock Soar 250%?

89bio Pulls Back With Market — But Could The Stock Soar 250%?

89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%.

Analyst Ratings for 89bio

Analyst Ratings for 89bio

89bio (NASDAQ:ETNB) has observed the following analyst ratings within the last quarter:

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022

Recap: 89bio Q1 Earnings

Recap: 89bio Q1 Earnings

89bio (NASDAQ:ETNB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings 89bio beat estimated earnings by 2.33%, reporting an EPS of $-1.26 versus an estimate of $-1.29.

89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health

89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health

89bio Inc (NASDAQ: ETNB)

Get all your
news in one place.

100's of premium titles.
One news app.

1

Organisations

American Express

Rivian Automotive

United Parcel Service

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

381,215 stories

140,494 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play